• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pharmacology of aztreonam after intravenous infusion.静脉输注后氨曲南的药理学。
Antimicrob Agents Chemother. 1983 Jul;24(1):18-22. doi: 10.1128/AAC.24.1.18.
2
Review of single- and multiple-dose pharmacokinetics of the monobactam, aztreonam (SQ 26,776) in healthy subjects.
Chemotherapy. 1983;29(5):313-21. doi: 10.1159/000238214.
3
Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic beta-lactam, in humans.单环β-内酰胺类药物Ro 17-2301(AMA-1080)在人体中的单剂量药代动力学。
Antimicrob Agents Chemother. 1984 Dec;26(6):898-902. doi: 10.1128/AAC.26.6.898.
4
Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.持续静脉输注氨曲南的药代动力学和药效学
Clin Ther. 1999 Nov;21(11):1882-9. doi: 10.1016/S0149-2918(00)86736-3.
5
Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects.健康受试者中单环β-内酰胺类氨曲南(SQ 26,776)的单剂量药代动力学。
Antimicrob Agents Chemother. 1982 Jun;21(6):944-9. doi: 10.1128/AAC.21.6.944.
6
How and why aztreonam works.氨曲南的作用方式及原因。
Surg Gynecol Obstet. 1990;171 Suppl:19-23.
7
Single-dose pharmacokinetics of aztreonam in healthy volunteers and renal failure patients.氨曲南在健康志愿者和肾衰竭患者中的单剂量药代动力学。
J Chemother. 1989 Jun;1(3):164-9. doi: 10.1080/1120009x.1989.11738886.
8
Single-dose pharmacokinetics of aztreonam in pediatric patients.氨曲南在儿科患者中的单剂量药代动力学。
Antimicrob Agents Chemother. 1984 Aug;26(2):196-9. doi: 10.1128/AAC.26.2.196.
9
Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects.单环β-内酰胺类药物氨曲南(SQ 26,776)在健康受试者中的多剂量药代动力学。
Antimicrob Agents Chemother. 1983 Jan;23(1):125-32. doi: 10.1128/AAC.23.1.125.
10
Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction.氨曲南在不同程度肾功能不全患者中的药代动力学。
Antimicrob Agents Chemother. 1983 Aug;24(2):252-61. doi: 10.1128/AAC.24.2.252.

引用本文的文献

1
Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK/PD Analysis.西班牙的药敏情况:通过药代动力学/药效学分析评估抗菌活性和耐药性抑制
Pharmaceutics. 2021 Nov 8;13(11):1899. doi: 10.3390/pharmaceutics13111899.
2
Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.头孢他啶阿维巴坦、克拉维酸、雷利巴坦和沃博巴坦对多重耐药嗜麦芽窄食单胞菌的活性。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.00297-20.
3
Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam.寻找针对产金属β-内酰胺酶和丝氨酸β-内酰胺酶肠杆菌科细菌的最佳治疗方案:氨曲南联合头孢他啶-阿维巴坦或美罗培南-瓦博巴坦。
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01426-19. Epub 2019 Sep 30.
4
Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.基于药代动力学-药效学模型及蒙特卡洛模拟的革兰氏阴性需氧菌抗菌药物断点值
J Antimicrob Chemother. 2008 Mar;61(3):621-8. doi: 10.1093/jac/dkm536. Epub 2008 Feb 4.
5
Clinical pharmacokinetics of aztreonam. An update.氨曲南的临床药代动力学。最新进展。
Clin Pharmacokinet. 1994 Feb;26(2):99-106. doi: 10.2165/00003088-199426020-00003.
6
Clinical pharmacokinetics of aztreonam in cancer patients.氨曲南在癌症患者中的临床药代动力学。
Antimicrob Agents Chemother. 1984 Oct;26(4):455-61. doi: 10.1128/AAC.26.4.455.
7
Pharmacokinetics of aztreonam in patients with chronic renal failure.
Clin Pharmacokinet. 1985 Jan-Feb;10(1):91-100. doi: 10.2165/00003088-198510010-00005.
8
Evaluation of aztreonam in the treatment of severe bacterial infections.氨曲南治疗严重细菌感染的评估。
Antimicrob Agents Chemother. 1985 Aug;28(2):222-6. doi: 10.1128/AAC.28.2.222.
9
Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.氨曲南。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1986 Feb;31(2):96-130. doi: 10.2165/00003495-198631020-00002.
10
Clinical pharmacokinetics of aztreonam.
Clin Pharmacokinet. 1988 Mar;14(3):148-55. doi: 10.2165/00003088-198814030-00003.

本文引用的文献

1
Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria.氨曲南(SQ 26,776),一种对需氧革兰氏阴性菌有特效的合成单环β-内酰胺抗生素。
Antimicrob Agents Chemother. 1982 Jan;21(1):85-92. doi: 10.1128/AAC.21.1.85.

静脉输注后氨曲南的药理学。

Pharmacology of aztreonam after intravenous infusion.

作者信息

Scully B E, Swabb E A, Neu H C

出版信息

Antimicrob Agents Chemother. 1983 Jul;24(1):18-22. doi: 10.1128/AAC.24.1.18.

DOI:10.1128/AAC.24.1.18
PMID:6684898
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC185098/
Abstract

The pharmacokinetics of aztreonam, a monocyclic beta-lactam which inhibits most members of the family Enterobacteriaceae at concentrations of less than 1 microgram/ml and most Pseudomonas aeruginosa isolates at concentrations of less than 16 micrograms/ml, were examined in healthy male volunteers after 30-min intravenous infusions of 0.5, 1, and 2 g of the drug. Mean peak levels of the drug in serum at the end of infusion were 65.5, 164, 255 micrograms/ml after 0.5 1, and 2 g, respectively, with levels of the drug in serum of 1.8, 3, and 8.5 micrograms/ml at 8.5 h for the three doses, respectively. The half-life was approximately 2 h for all three doses. The total serum clearance averaged 1 ml/min per kg. The apparent volume of distribution averaged 0.17 liter/kg for the three doses. Overall excretion of the drug in urine was 61%, with mean levels in urine of 23, 52, and 109 micrograms/ml at 8.5 to 12.5 h after 0.5, 1, and 2 g of aztreonam, respectively. Concentrations of the drug in serum after a 1-g dose exceeded the minimal inhibitory concentration for 90% of the members of the Enterobacteriaceae by four- to eightfold for 8 h and exceeded the minimal inhibitory concentration for P. aeruginosa isolates for 4 h.

摘要

氨曲南是一种单环β-内酰胺类抗生素,在浓度低于1微克/毫升时可抑制大多数肠杆菌科细菌,在浓度低于16微克/毫升时可抑制大多数铜绿假单胞菌菌株。在健康男性志愿者中,静脉输注0.5克、1克和2克该药30分钟后,对其药代动力学进行了研究。输注结束时血清中药物的平均峰值水平在给予0.5克、1克和2克后分别为65.5、164、255微克/毫升,三个剂量在8.5小时时血清中药物水平分别为1.8、3和8.5微克/毫升。三个剂量的半衰期均约为2小时。总血清清除率平均为每千克体重1毫升/分钟。三个剂量的表观分布容积平均为0.17升/千克。药物在尿液中的总排泄率为61%,给予0.5克、1克和2克氨曲南后,在8.5至12.5小时尿液中的平均水平分别为23、52和109微克/毫升。给予1克剂量后,血清中药物浓度超过肠杆菌科90%成员的最低抑菌浓度4至8倍,持续8小时,超过铜绿假单胞菌菌株的最低抑菌浓度,持续4小时。